Which companies overlap with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano's portfolio?

Top competitors by shared drug class: Dutch Colorectal Cancer Group.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fondazione-irccs-istituto-nazionale-dei-tumori-milano.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline: 0 marketed, 0 filed, 0 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 8 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dutch Colorectal Cancer Group · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fondazione IRCCS Istituto Nazionale dei Tumori, Milano:

Cite this brief

Drug Landscape (2026). Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fondazione-irccs-istituto-nazionale-dei-tumori-milano. Accessed 2026-05-16.